by
Gus Iversen, Editor in Chief | November 03, 2025
SpectronRx has launched commercial-scale production of Actinium-225 (Ac-225), aiming to ease a global shortage of the isotope used in targeted cancer therapies.
The Indianapolis-based contract development and manufacturing organization (CDMO) is using a proprietary accelerator-based method to produce high-purity Ac-225. Historically, limited supply of the isotope has constrained clinical development of radiopharmaceuticals that rely on its alpha-emitting properties to selectively destroy tumor cells while sparing healthy tissue.
“This marks a significant milestone for our company, our clients and the patients who will benefit from the advancements in Actinium-225-labeled drug products,” said John Zehner, CEO of SpectronRx.
Ad Statistics
Times Displayed: 344592
Times Visited: 21056 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Ac-225 is central to a growing number of investigational radiopharmaceuticals, many of which are progressing through early-phase trials. With rising demand, several manufacturers have faced bottlenecks due to limited production capacity. SpectronRx says its technology enables a scalable and consistent supply, which could help accelerate drug development timelines and reduce clinical delays.
“Our team has successfully scaled a robust process for manufacturing high-purity Ac-225, and we are ready to supply the market,” said Anwer Rizvi, president of SpectronRx. “We have established the quality systems and manufacturing capacity to support our partners from early-phase clinical trials through to commercial launch.”
SpectronRx currently operates multiple accelerators capable of Ac-225 production and plans further expansion to meet global needs. The company’s facilities span more than 250,000 square feet across five sites in the U.S. and Europe, with more than 50 hot cells and clean rooms. It supplies radiolabeled drug products to 29 countries and partners with over 30 pharmaceutical and biotech firms.
The development comes as interest grows in alpha therapies, which offer potential advantages over beta emitters in treating certain cancers, particularly when dealing with small or residual disease.
